Noxopharm has been disparaged repeatedly by Harvett for having...

Noxopharm has been disparaged repeatedly by Harvett for having no granted Patents.  Will he be man enough to acknowledge that this is no longer the case?

Last year Harvett wrote that: “Even if successful, anyone can still use idronoxil via IP, oral or even a suppository to reach the same pharmacokinetics that have been improved with Veyonda as dosing levels are not usually patentable”.  This is utter nonsense.

Noxopharm provided proof in its patent applications that when Idronoxil was used in IP, Oral or admixed Suppository formulations it had a very short half-life and was therefore ineffective.  By contrast, when Idronoxil was dissolved in the suppository base the half life became >10 hours, which meant that twice-daily doses ensured that Idronoxil was active around the clock.

Warren Buffet likes to invest in companies that are protected by a ‘moat’; an in-built dominance that inhibits competitors.  Noxopharm’s strategy is to build a moat around NOX66 by patenting the method of formulation, the new formulation itself, and its interaction with chemotherapy, radiation, LuPSMA and Immuno-Oncology targets.   If Noxopharm has Patent protection over Idronoxil dissolved in a suppository base, it means that anyone who wants to use Idronoxil in that way will either have to sign a Licence agreement, or buy Noxopharm.